Morepen Laboratories Ltd

The newly formed wholly owned subsidiary namely Morepen Labs ' FZCO, will trade in pharmaceuticals/ medicines (outside UAE). The company has subscribed 5000 ordinary shares of AED 10 each, aggregating to AED 50,000. The incorporated entity being a wholly owned subsidiary, is a related party of the company. Morepen Laboratories is a vertically integrated, innovation-led pharmaceutical and healthcare company delivering highquality APIs, branded generics, medical devices, and consumer wellness products to over 80 countries worldwide. The company's consolidated net profit declined 28.18% to Rs 20.31 crore despite a 10.11% jump in revenue from operations to Rs 465.85 crore in Q4 FY25 over Q4 FY24. The counter declined 2.29% to settle at Rs 62.23 on the BSE. Powered by Capital Market - Live

The Board of Morepen Laboratories at its meeting held on 23 May 2025 has approved inter-alia, availing of working capital demand loan facility, packing credit facility and post shipment facility from Qatar National Bank, to the extent of, in aggregate, Rs. 50 crore and entered into various agreements with the Bank.Powered by Capital Market - Live

The Board of Morepen Laboratories at its meeting held on 12 May 2025 has noted the decision of the Board of Directors of Morepen Medipath (formerly known as Morepen Medtech), a subsidiary of the Company, to incorporate a Wholly Owned Subsidiary in the mainland at Dubai, United Arab Emirates. The incorporation of the wholly owned subsidiary is intended to expand both the Business-to-Consumer (B2C) and Business-to-Business (B2B) customer segments and to provide greater access to the medical device business. Upon incorporation, the proposed company will become a step-down subsidiary of Morepen Laboratories. Powered by Capital Market - Live

Net profit of Morepen Laboratories declined 28.15% to Rs 20.32 crore in the quarter ended March 2025 as against Rs 28.28 crore during the previous quarter ended March 2024. Sales rose 10.11% to Rs 465.85 crore in the quarter ended March 2025 as against Rs 423.07 crore during the previous quarter ended March 2024. For the full year,net profit rose 22.73% to Rs 118.02 crore in the year ended March 2025 as against Rs 96.16 crore during the previous year ended March 2024. Sales rose 7.17% to Rs 1811.58 crore in the year ended March 2025 as against Rs 1690.43 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales465.85423.07 10 1811.581690.43 7 OPM %9.0711.44 -9.619.38 - PBDT42.1851.83 -19 184.09168.89 9 PBT25.7142.20 -39 155.11135.42 15 NP20.3228.28 -28 118.0296.16 23 Powered by Capital Market - Live

Morepen Laboratories announced that the Board of Directors of the Company at its meeting held on 12 May 2025, has recommended a Final Dividend of Rs.0.20 per share (i.e.10%), subject to the approval of the shareholders.Powered by Capital Market - Live

Morepen Laboratories will hold a meeting of the Board of Directors of the Company on 12 May 2025.Powered by Capital Market - Live

Morepen Laboratories has got clearance from Subject Expert Committee (SEC) of Central Drugs Standard Control Organization (CDSCO) to conduct Bioequivalence (BE) studies for Resmetirom 60 mg, 80 mg and 100 mg tablets as per the protocol submitted. This will be followed by clinical trials as per approved protocols. Resmetirom is a highly promising therapy under development for non-alcoholic steatohepatitis ('NASH'), a serious form of non-alcoholic fatty liver disease (NAFLD) characterized by inflammation, liver damage, and fat accumulation in the liver, potentially leading to scarring (fibrosis), cirrhosis, and even liver cancer. It is often associated with obesity, metabolic syndrome, and type 2 diabetes, and while it can be a silent disease in the early stages, it can progress to severe liver damage if left untreated. As one of the first Indian companies to foray into this therapeutic area, Morepen is strategically positioned to serve both domestic and international markets and is also evaluating out-licencing opportunities with potential marketing partners.Powered by Capital Market - Live

Morepen Laboratories announced the launch of four new products'Ticapen, UdoFix, LycoMore, Acifix in the month of April 2025 to cater the domestic market in addition to Empamore launched last month continuing. This strategic expansion reinforces Morepen's commitment to scaling its finished dosages business while continuing to invest in cutting-edge R&D that powers a robust pipeline of differentiated, high quality medicines. Importantly, all APIs used in these products are manufactured in-house by Morepen at its world-class, USFDA-approved plants, ensuring consistent quality and supply chain control. Powered by Capital Market - Live

The move is aimed at strengthening Morepen's connect with doctors, pharmacies, patients, and healthcare professionals nationwide. It marks a bold step in scaling up the company's formulations business, which currently stands at around Rs 325 crore. Morepen has set its sights on building a Rs 1,000 crore finished dosages segment within the next five years. To achieve this, the company plans aggressive expansion of its medical representative network and deeper market penetration across both urban and rural India. A key driver of this growth will be its pipeline of competitively priced new products already in production. The Indian pharmaceutical market, projected to reach $130 billion by 2030 with an annual growth rate of 8.2%, positions India as the emerging pharmacy of the world'offering a strong runway for players like Morepen. Morepen Laboratories' operations span APIs, medical devices, and finished formulations. The company is a global exporter of six major APIs, including Loratadine, Montelukast, Desloratadine, Atorvastatin, and Fexofenadine. In the medical devices segment, Morepen has installed over 12.33 million glucometers and sold nearly 1.65 billion blood glucose strips, supporting its expansion into tier-2 and tier-3 cities. The company's consolidated net profit fell 16.6% to Rs 26.69 crore while revenue from operations rose 1.9% to Rs 452.78 crore in Q3 December 2024 over Q3 December 2023. Powered by Capital Market - Live

Morepen Laboratories today announced a bold expansion plan aimed at deepening its connect with doctors, patients, pharmacies, and healthcare professionals across the country. As part of this strategic initiative, the company will add more than 1,000 professionals to its salesforce over the next three years, with over 200 team members expected to join in FY26 alone. This expansion represents a pivotal moment in Morepen's journey as we sharpen our focus on the expanding domes c finished dosage market, said Sushil Suri, Chairman and Managing Director of Morepen Laboratories. With the leadership in our high value APIs, this significant increase in our salesforce and enhanced reach to doctors, pharmacies, and patients, we are se ng the stage for getting a bigger pie in the Indian pharmaceutical market valued at ₹2.38 lakh crore, yielding higher gross margins and be er returns for stakeholders in the long run.'Powered by Capital Market - Live